Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the renal cell carcinoma market grown in recent years?

The market size for renal cell carcinoma has seen a robust growth in the past few years. It is anticipated that this market will thrive from $0.69 billion in 2024 to $0.74 billion in 2025, with a yearly growth rate of 7.0%. The substantial growth during the historical period has its roots in the upsurge in kidney cancer cases, an increment in the ageing population, an evolving inclination towards targeted therapies, an improved consciousness regarding cancer diagnoses, advancements in the healthcare infrastructure, and an increase in funding towards research and development in oncology.

How is the renal cell carcinoma market size expected to evolve during the forecast period?

The market size for renal cell carcinoma is predicted to exhibit robust growth in the coming years, reaching $0.95 billion by 2029 with a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this projected increase during the forecast period include the growing usage of personalized medicine, enhanced consciousness about early detection of cancer, increased healthcare expenditures on oncology, better healthcare access, and additional clinical trials and research on innovative treatments. Key trends anticipated for this period are the incorporation of AI in precise diagnostics, designing of targeted treatments, breakthroughs in immunotherapy, progress in identifying biomarkers, acceptance of minimal invasive surgical methods, and advancements in imaging technologies.

Get your renal cell carcinoma market report here!

https://www.thebusinessresearchcompany.com/report/renal-cell-carcinoma-global-market-report

Which key drivers are propelling the renal cell carcinoma market’s growth?

The surge in the aging population is anticipated to fuel the expansion of the renal cell carcinoma market in the future. The aging population includes elderly individuals, typically over the age of 65, who may have special healthcare and social needs. This increase is fueled by improvements in healthcare, enhanced nutrition, and extended lifespan. The frequency of Renal Cell Carcinoma (RCC) is growing among the elderly, emphasizing the necessity for unique screening and treatment plans for this age bracket. For instance, according to a report released by the Population Reference Bureau, a US-based non-profit organization that collects data for research and academic uses, in January 2024, the count of America’s individuals aged 65+ is predicted to jump from 58 million in 2022 to 82 million by 2050, reflecting a 47% growth. Hence, the escalating aging population is the driving force behind the renal cell carcinoma market’s growth.

What are the market segments in the renal cell carcinoma industry?

The renal cell carcinoma market covered in this report is segmented –

1) By Type: Clear Cell Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma (RCC)

2) By Diagnosis: Urine Tests, Computed Tomography (CT) Scan, Nephrectomy, Blood Tests, Ultrasound, Biopsy

3) By Treatment: Medication, Ablation, Targeted Therapy, Chemotherapy, Surgery, Other Treatments

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Clear Cell Renal Cell Carcinoma (RCC): Sporadic Clear Cell RCC, Hereditary Clear Cell RCC

2) By Papillary Renal Cell Carcinoma (RCC): Type 1 Papillary RCC, Type 2 Papillary RCC

3) By Chromophobe Renal Cell Carcinoma (RCC): Classic Chromophobe RCC, Hybrid Chromophobe RCC

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20944&type=smp

Which leading companies are shaping the growth of the renal cell carcinoma market?

Major companies operating in the renal cell carcinoma market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, Fresenius Kabi AG, GSK plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc. (Mylan N.V.), Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Cipla Inc., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Exelixis Inc., Nektar Therapeutics

What emerging trends are influencing the growth of the renal cell carcinoma market?

Major companies operating in the renal cell carcinoma market are focusing on developing technologically advanced products, such as integrating artificial intelligence (AI)-powered solutions designed for the analysis of kidney biopsies to enhance diagnostic accuracy, streamline procedures, and improve patient outcomes. An artificial intelligence (AI)–powered solution for analyzing kidney biopsies is a technology-driven tool that leverages machine learning algorithms and computer vision to assist pathologists and nephrologists in evaluating kidney tissue samples. These solutions aim to enhance accuracy, efficiency, and consistency in diagnosing kidney diseases and assessing kidney health. For instance, in March 2024, Aiosyn, a Netherlands-based software company, launched the NephroPath platform, an advanced AI-powered solution designed to analyze kidney biopsies. The NephroPath platform uses computational pathology algorithms to analyze histological biomarkers in kidney biopsies, including identifying tissue types, measuring interstitial fibrosis, and precisely counting and assessing glomeruli. This AI-driven analysis ensures consistent, detailed, and reproducible scoring of renal pathology biomarkers, overcoming the drawbacks of traditional scoring methods and observer subjectivity.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20944

Which geographic areas are influencing the growth of the renal cell carcinoma market?

North America was the largest region in the renal cell carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renal cell carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Renal Biomarkers Global Market Report 2025

https://thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

End Stage Renal Disease (ESRD) Drug Global Market Report 2025

https://thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

Hepatorenal Syndrome Treatment Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/hepatorenal-syndrome-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: